Press Resease

Global Thalassemia Market - by Type (Hb Bart Syndrome Or Hemoglobin Bart Hydrops Fetalis Syndrome, Silent Carrier State, Hbh Disease, Trait), by Diagnosis (Prenatal Testing, Perinatal Testing, Pre-Implantation), by Treatment (Iron Chelation, Blood Transfusions, Stem Cell Transplant Or Bone Marrow, Gene Therapy Surgery), by End-User (Pharmaceutical Industries, Biotechnological Laboratories, Hospitals, Educational Research Institutes, Diagnostic Laboratories, Others), and by Region: Latest Industry Insights, Comprehensive Analysis and Forecast, 2019 – 2026

Published Date: 21-Aug-2020 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-2880 Status : Published

Global Thalassemia Market was valued at USD 2.30 Billion in 2019 and is expected to reach over USD 4.54 Billion by 2026, growing at a CAGR of around 10.2% during the forecast period from 2020 to 2026

Description

According to the report, the global Thalassemia Market was valued at USD 2.30 Billion in 2019 and is expected to reach over USD 4.54 Billion by 2026, growing at a CAGR of around 10.2% during the forecast period from 2020 to 2026.

The global Thalassemia market is expected to expand due to rising prevalence of the disease across entire world. Advancements in healthcare such as gene therapy, stem cell therapy etc. has opened new avenues for incurable diseases. Rising awareness of people towards healthcare expenditure by governments has compelled policymakers to increase spending on healthcare.

Global Thalassemia Market: Overview

Thalassemia is an exceptional genetic blood disorder majorly characterized by the generation of abnormal hemoglobin, which is accountable for the damage of red blood cells, which mainly lead to anemia. Iron chelation therapies and blood transfusion are the only cure alternatives accessible at present. This gives augment to abundant opportunities and prospects in the market for expansion of the worldwide curative cure for thalassemia.

Global Thalassemia Market

Global Thalassemia Market: Growth Factors

Augment in the occurrence of thalassemia is projected to propel market development. In spite of technological developments, the unmet requirement for a consistent treatment alternative still exists. Healing or treatment process of thalassemia is mainly limited to usual iron chelation and blood transfusions therapy. Medicines or drugs prescribed for thalassemia mainly cures symptoms as well as side effects, for instance, iron overload, anemia, and vitamin shortage. On the other hand, gene therapy is up-coming as a consistent treatment choice for the syndrome. The occurrence of thalassemia is expected to augment steadily in the coming years across various regions. This can be accredited to inhabitant’s migration, environmental & genetic, and intermarriages aspects prompting the issue as well as its implications. All these factors are expected to boost the global thalassemia market.

Global Thalassemia Market: Segmentation

The global thalassemia market is categorized in terms of type, treatment, diagnosis, and end-users. In terms of type, the market is classified into Hb Bart syndrome or hemoglobin Bart hydrops fetalis syndrome, silent carrier state, HbH disease, and trait. In terms of diagnosis, the thalassemia market is fragmented into prenatal testing, perinatal testing, and pre-implantation. Further, the perinatal testing division is sub-divided into DNA testing and complete blood count (CBC). The prenatal testing division is categorized into chorionic villus sampling and prenatal genetic testing. In terms of the treatment, the market is divided into iron chelation, blood transfusions, stem cell transplant or bone marrow, gene therapy and surgery. In terms of the end-user, the thalassemia market is likely to be divided into pharmaceutical industries, biotechnological laboratories, hospitals, educational research institutes, diagnostic laboratories, and others.

Global Thalassemia Market: Regional Analysis

In terms of region, the global thalassemia market mainly includes the Americas, Asia Pacific, Europe, and the Middle East & Africa. North America is anticipated to hold the highest market share which is likely to be followed by Europe. The global thalassemia market is likely to experience a growing trend particularly in the countries with ethnic grouping such as African countries, Mediterranean countries as well as few countries in the Asia Pacific. As currently, migration is becoming very common, the inhabitants of thalassemia are expected to increase specifically in the developed countries. There are numerous prenatal tests accessible in the market to find out the possibility of thalassemia comprising both invasive as well as non-invasive method. A recent development in the global thalassemia market may resolve the risk of the syndrome in vitro check of the embryo. Though there are several tests accessible in the global market however lack of knowledge leads to the slackness and delayed treatment of the diseased state in several regions.

Global Thalassemia Market: Competitive Players

Some of the most important market players in the global thalassemia market are Bluebird Bio, Lonza Group Ltd., Sangamo Bioscience, Acceleron Pharma, Inc., and Kiadis Pharma., among others.

Global Thalassemia Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • The UK
    • France
    • Germany
  • The Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

What Reports Provides

  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.

Table Of Content

  • Chapter 1 Preface
    • 1.1 Report Description
    • 1.1 Report Scope
  • Chapter 2 Research Methodology
    • 2.1 Research Methodology
    • 2.2 Secondary Research
    • 2.3 Primary Research
    • 2.4 Models
      • 2.4.1 Company Share Analysis Model
      • 2.4.2 Revenue Based Modeling
    • 2.5 Research Limitations
  • Chapter 3 Executive Summary
    • 3.1 Global Thalassemia Market, 2016 – 2026 (USD Billion)
    • 3.2 Global Thalassemia Market: Snapshot
  • Chapter 4 Thalassemia Market – Industry Analysis
    • 4.1 Introduction
    • 4.2 Market Drivers
      • 4.2.1 Driving Factor 1 Analysis
      • 4.2.2 Driving Factor 2 Analysis:
    • 4.3 Market Restraints
      • 4.3.1 Restraining Factor Analysis
    • 4.4 Market Opportunities
      • 4.4.1 Market Opportunity & Use-case Analysis
      • 4.4.2 Use – Cases for Thalassemia
    • 4.5 Porter’s Five Forces Analysis
    • 4.6 COVID 19 Impact Analysis
      • 4.6.1.1 Impact on Product Development and Technology Adoption
      • 4.6.1.2 Gap Analysis
  • Chapter 5 Investment Proposition Analysis
    • 5.1 Global Thalassemia Market Attractiveness, By Type
    • 5.2 Global Thalassemia Market Attractiveness, By Diagnosis
    • 5.3 Global Thalassemia Market Attractiveness, By End-User
    • 5.4 Global Thalassemia Market Attractiveness, By Region
  • Chapter 6 Competitive Landscape
    • 6.1 Company Market Share Analysis - 2019
      • 6.1.1 Global Thalassemia Market: Company Market Share, 2019
    • 6.2 Strategic Developments
    • 7.1 Global Thalassemia Market Overview: by Type
      • 7.1.1 Global Thalassemia Market Revenue Share, by Type, 2019 & 2026
    • 7.2 Global Thalassemia Market Analysis/Overview – By Type
      • 7.2.1 Hb Bart Syndrome – Overview/Analysis
      • 7.2.2 Silent Carrier State – Overview/Analysis
      • 7.2.3 Hbh Disease – Overview/Analysis
    • 7.3 Hb Bart Syndrome
      • 7.3.1 Global Thalassemia Market for Hb Bart Syndrome, Revenue (USD Billion) 2016 - 2026
    • 7.4 Silent Carrier State
      • 7.4.1 Global Thalassemia Market for Silent Carrier State, Revenue (USD Billion) 2016 - 2026
    • 7.5 Hbh Disease
      • 7.5.1 Global Thalassemia Market for Hbh Disease, Revenue (USD Billion) 2016 - 2026
    • 8.1 Global Thalassemia Market Overview: by Diagnosis
      • 8.1.1 Global Thalassemia Market Revenue Share, by Diagnosis, 2019 & 2026
    • 8.2 Global Thalassemia Market Analysis/Overview – By Diagnosis
      • 8.2.1 Prenatal Testing – Overview/Analysis
      • 8.2.2 Perinatal Testing – Overview/Analysis
      • 8.2.3 Pre-Implantation – Overview/Analysis
    • 8.3 Prenatal Testing
      • 8.3.1 Global Thalassemia Market for Prenatal Testing, Revenue (USD Billion) 2016 - 2026
    • 8.4 Perinatal Testing
      • 8.4.1 Global Thalassemia Market for Perinatal Testing, Revenue (USD Billion) 2016 - 2026
    • 8.5 Pre-Implantation
      • 8.5.1 Global Thalassemia Market for Pre-Implantation, Revenue (USD Billion) 2016 - 2026
    • 9.1 Global Thalassemia Market Overview: by End-User
      • 9.1.1 Global Thalassemia Market Revenue Share, by End-User, 2019 & 2026
    • 9.2 Global Thalassemia Market Analysis/Overview – By End-User
      • 9.2.1 Pharmaceutical Industries – Overview/Analysis
      • 9.2.2 Biotechnulogical Laboratories – Overview/Analysis
      • 9.2.3 Hospital – Overview/Analysis
      • 9.2.4 Educational Research Institutes – Overview/Analysis
      • 9.2.5 Diagnostic Laboratories – Overview/Analysis
      • 9.2.6 Others – Overview/Analysis
    • 9.3 Pharmaceutical Industries
      • 9.3.1 Global Thalassemia Market for Pharmaceutical Industries, Revenue (USD Billion) 2016 - 2026
    • 9.4 Biotechnulogical Laboratories
      • 9.4.1 Global Thalassemia Market for Biotechnulogical Laboratories, Revenue (USD Billion) 2016 - 2026
    • 9.5 Hospital
      • 9.5.1 Global Thalassemia Market for Hospital, Revenue (USD Billion) 2016 - 2026
    • 9.6 Educational Research Institutes
      • 9.6.1 Global Thalassemia Market for Educational Research Institutes, Revenue (USD Billion) 2016 - 2026
    • 9.7 Diagnostic Laboratories
      • 9.7.1 Global Thalassemia Market for Diagnostic Laboratories, Revenue (USD Billion) 2016 - 2026
    • 9.8 Others
      • 9.8.1 Global Thalassemia Market for Others, Revenue (USD Billion) 2016 - 2026
  • Chapter 10 Thalassemia Market – Regional Analysis
    • 10.1 Global Thalassemia Market: Regional Overview
      • 10.1.1 Global Thalassemia Market Revenue Share, by Region, 2019 & 2026
      • 10.1.2 Global Thalassemia Market Revenue, by Region, 2016 – 2026 (USD Billion)
    • 10.2 North America
      • 10.2.1 North America Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
      • 10.2.2 North America Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.2.3 North America Thalassemia Market Revenue, by Type, 2016 – 2026
      • 10.2.4 North America Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
      • 10.2.5 North America Thalassemia Market Revenue, by End-User, 2016 – 2026
      • 10.2.6 U.S.
      • 10.2.7 Canada
    • 10.3 Europe
      • 10.3.1 Europe Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
      • 10.3.2 Europe Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.3.3 Europe Thalassemia Market Revenue, by Type, 2016 – 2026
      • 10.3.4 Europe Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
      • 10.3.5 Europe Thalassemia Market Revenue, by End-User, 2016 – 2026
      • 10.3.6 Germany
      • 10.3.7 France
      • 10.3.8 U.K.
      • 10.3.9 Rest of Europe
    • 10.4 Asia Pacific
      • 10.4.1 Asia Pacific Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
      • 10.4.2 Asia Pacific Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.4.3 Asia Pacific Thalassemia Market Revenue, by Type, 2016 – 2026
      • 10.4.4 Asia Pacific Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
      • 10.4.5 Asia Pacific Thalassemia Market Revenue, by End-User, 2016 – 2026
      • 10.4.6 China
      • 10.4.7 India
      • 10.4.8 Rest of Asia Pacific
    • 10.5 Latin America
      • 10.5.1 Latin America Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
      • 10.5.2 Latin America Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.5.3 Latin America Thalassemia Market Revenue, by Type, 2016 – 2026
      • 10.5.4 Latin America Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
      • 10.5.5 Latin America Thalassemia Market Revenue, by End-User, 2016 – 2026
      • 10.5.6 Brazil
      • 10.5.7 Rest of Latin America
    • 10.6 The Middle-East and Africa
      • 10.6.1 The Middle-East and Africa Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
      • 10.6.2 The Middle-East and Africa Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
      • 10.6.3 The Middle-East and Africa Thalassemia Market Revenue, by Type, 2016 – 2026
      • 10.6.4 The Middle-East and Africa Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
      • 10.6.5 The Middle-East and Africa Thalassemia Market Revenue, by End-User, 2016 – 2026
      • 10.6.6 GCC Countries
      • 10.6.7 Rest of Middle-East Africa
  • Chapter 11 Company Profiles
    • 11.1 Bluebird Bio
      • 11.1.1 Company Overview
      • 11.1.2 Financial Overview
      • 11.1.3 Product Portfolio
      • 11.1.4 Business Strategy
      • 11.1.5 Recent Developments
    • 11.2 Lonza Group Ltd
    • 11.3 Sangamo Bioscience
    • 11.4 Acceleron Pharma, Inc.
    • 11.5 Kiadis Pharma

Methodology

}